Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from TELA Bio ( (TELA) ) is now available.
TELA Bio reported first quarter 2026 revenue of $19.1 million, a 3% increase year over year with 13% unit growth, driven mainly by expanding international sales and strong European momentum, including 41% revenue growth in Europe. Despite flat operating expenses of $23.0 million and a stable $10.5 million operating loss, net loss widened slightly to $12.3 million, while cash and cash equivalents stood at $39.5 million as of March 31, 2026.
The company completed staffing its U.S. commercial organization, announced a strategic board refreshment effective after the June 9, 2026 annual meeting, and launched OviTex LTR in the U.S., a fully resorbable, tissue-based hernia repair solution that broadens its portfolio. Management reiterated full-year 2026 revenue guidance of at least 8% growth over 2025 and projected second-quarter 2026 revenue of about $20.0 million, signaling confidence in achieving predictable growth despite ongoing losses.
The most recent analyst rating on (TELA) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
Spark’s Take on TELA Stock
According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.
The score is primarily constrained by weak financial quality (continued losses, cash burn, and higher leverage). Momentum has improved technically, but overbought signals temper it. Guidance suggests continued growth and narrowing losses but with notable execution risks, and the Nasdaq deficiency notice adds additional downside risk.
To see Spark’s full report on TELA stock, click here.
More about TELA Bio
TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that prioritize preservation and restoration of the patient’s own anatomy. The company provides advanced, economically effective products that leverage natural healing responses while aiming to minimize long-term exposure to permanent synthetic materials, with a growing U.S. and European market presence.
Average Trading Volume: 179,069
Technical Sentiment Signal: Sell
Current Market Cap: $45.64M
Find detailed analytics on TELA stock on TipRanks’ Stock Analysis page.